TY - STD TI - Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73. [cited 2019 Jan 30]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858828/. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858828/ ID - ref1 ER - TY - JOUR AU - Leach, D. R. AU - Krummel, M. F. AU - Allison, J. P. PY - 1996 DA - 1996// TI - Enhancement of antitumor immunity by CTLA-4 blockade JO - Science. VL - 271 UR - https://doi.org/10.1126/science.271.5256.1734 DO - 10.1126/science.271.5256.1734 ID - Leach1996 ER - TY - JOUR AU - Sharma, P. AU - Allison, J. P. PY - 2015 DA - 2015// TI - Immune checkpoint targeting in Cancer therapy: toward combination strategies with curative potential JO - Cell. VL - 161 UR - https://doi.org/10.1016/j.cell.2015.03.030 DO - 10.1016/j.cell.2015.03.030 ID - Sharma2015 ER - TY - JOUR AU - Oiseth, S. J. AU - Aziz, M. S. PY - 2017 DA - 2017// TI - Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead JO - J Cancer Metastasis Treat VL - 3 UR - https://doi.org/10.20517/2394-4722.2017.41 DO - 10.20517/2394-4722.2017.41 ID - Oiseth2017 ER - TY - JOUR AU - Serrano, P. AU - Hartmann, M. AU - Schmitt, E. AU - Franco, P. AU - Amexis, G. AU - Gross, J. PY - 2019 DA - 2019// TI - Clinical development and initial approval of novel immune checkpoint inhibitors in oncology: insights from a global regulatory perspective JO - Clin Pharmacol Ther VL - 105 UR - https://doi.org/10.1002/cpt.1123 DO - 10.1002/cpt.1123 ID - Serrano2019 ER - TY - STD TI - European Medicines Agency (EMA). Conditional marketing authorisation: Report on ten years of experience at the European Medicines Agency [Internet]. 2017 [cited 2019 Jun 27]. Available from: https://www.ema.europa.eu/en/documents/report/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf. UR - https://www.ema.europa.eu/en/documents/report/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf ID - ref6 ER - TY - STD TI - European Medicines Agency (EMA). Assessment report EMEA/H/C/WS1550 [Internet]. 2019 Sep [cited 2020 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/variation-report/taxotere-h-c-ws1550-epar-assessment-report-variation_en.pdf. UR - https://www.ema.europa.eu/en/documents/variation-report/taxotere-h-c-ws1550-epar-assessment-report-variation_en.pdf ID - ref7 ER - TY - STD TI - European Medicines Agency (EMA). Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man: EMA/CHMP/27994/2008/Rev.1 [Internet]. 2012 Dec [cited 2020 Apr 20]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using_en.pdf. UR - https://www.ema.europa.eu/en/documents/scientific-guideline/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using_en.pdf ID - ref8 ER - TY - STD TI - Latimer NR. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials - Extrapolation with Patient-Level Data [Internet]. 2011 [cited 2019 Jan 18]. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. UR - http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf ID - ref9 ER - TY - JOUR AU - Latimer, N. R. PY - 2013 DA - 2013// TI - Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide JO - Med Decis Mak VL - 33 UR - https://doi.org/10.1177/0272989X12472398 DO - 10.1177/0272989X12472398 ID - Latimer2013 ER - TY - JOUR AU - Bagust, A. AU - Beale, S. PY - 2014 DA - 2014// TI - Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach JO - Med Decis Mak Int J Soc Med Decis Mak VL - 34 UR - https://doi.org/10.1177/0272989X13497998 DO - 10.1177/0272989X13497998 ID - Bagust2014 ER - TY - JOUR AU - Clark, T. G. AU - Bradburn, M. J. AU - Love, S. B. AU - Altman, D. G. PY - 2003 DA - 2003// TI - Survival analysis part IV: further concepts and methods in survival analysis JO - Br J Cancer VL - 89 UR - https://doi.org/10.1038/sj.bjc.6601117 DO - 10.1038/sj.bjc.6601117 ID - Clark2003 ER - TY - STD TI - Royston P, Lambert PC. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model [Internet]. StataCorp LP; 2011 [cited 2019 Jun 28]. Available from: https://econpapers.repec.org/bookchap/tsjspbook/fpsaus.htm. UR - https://econpapers.repec.org/bookchap/tsjspbook/fpsaus.htm ID - ref13 ER - TY - JOUR AU - Grieve, R. AU - Hawkins, N. AU - Pennington, M. PY - 2013 DA - 2013// TI - Extrapolation of survival data in cost-effectiveness analyses: improving the current state of play JO - Med Decis Mak Int J Soc Med Decis Mak. VL - 33 UR - https://doi.org/10.1177/0272989X13492018 DO - 10.1177/0272989X13492018 ID - Grieve2013 ER - TY - JOUR AU - Vanni, T. AU - Karnon, J. AU - Madan, J. AU - White, R. G. AU - Edmunds, W. J. AU - Foss, A. M. PY - 2011 DA - 2011// TI - Calibrating models in economic evaluation: a seven-step approach JO - PharmacoEconomics. VL - 29 UR - https://doi.org/10.2165/11584600-000000000-00000 DO - 10.2165/11584600-000000000-00000 ID - Vanni2011 ER - TY - STD TI - Commonwealth of Australia as represented by the Department of Health. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee (Version 5.0) [Internet]. 2016 Sep [cited 2019 Jun 28]. Available from: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf. UR - https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf ID - ref16 ER - TY - STD TI - The Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada (4th Edition) [Internet]. 2017 [cited 2019 May 31]. Available from: https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf. UR - https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf ID - ref17 ER - TY - STD TI - National Centre for Pharmacoeconomics (NCPE). Applicant template for submission of full pharmacoeconomic assessments to the National Centre for Pharmacoeconomics National Centre for Pharmacoeconomics (NCPE). Version 5.1, last updated on 2018 July 12. Microsoft Word document. Cited 31 May 2019. Available from: http://www.ncpe.ie/wp-content/uploads/2018/08/NCPE-submission-applicant-template-v1.5.dox_-1.docx. UR - http://www.ncpe.ie/wp-content/uploads/2018/08/NCPE-submission-applicant-template-v1.5.dox_-1.docx ID - ref18 ER - TY - JOUR AU - Kaufman, H. L. AU - Russell, J. AU - Hamid, O. AU - Bhatia, S. AU - Terheyden, P. AU - D’Angelo, S. P. PY - 2016 DA - 2016// TI - Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30364-3 DO - 10.1016/S1470-2045(16)30364-3 ID - Kaufman2016 ER - TY - JOUR AU - Becker, J. C. AU - Lorenz, E. AU - Ugurel, S. AU - Eigentler, T. K. AU - Kiecker, F. AU - Pföhler, C. PY - 2017 DA - 2017// TI - Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.19218 DO - 10.18632/oncotarget.19218 ID - Becker2017 ER - TY - JOUR AU - Cowey, C. L. AU - Mahnke, L. AU - Espirito, J. AU - Helwig, C. AU - Oksen, D. AU - Bharmal, M. PY - 2017 DA - 2017// TI - Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA JO - Future Oncol Lond Engl VL - 13 UR - https://doi.org/10.2217/fon-2017-0187 DO - 10.2217/fon-2017-0187 ID - Cowey2017 ER - TY - JOUR AU - Iyer, J. G. AU - Blom, A. AU - Doumani, R. AU - Lewis, C. AU - Tarabadkar, E. S. AU - Anderson, A. PY - 2016 DA - 2016// TI - Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma JO - Cancer Med VL - 5 UR - https://doi.org/10.1002/cam4.815 DO - 10.1002/cam4.815 ID - Iyer2016 ER - TY - JOUR AU - Kaufman, H. L. AU - Russell, J. S. AU - Hamid, O. AU - Bhatia, S. AU - Terheyden, P. AU - D’Angelo, S. P. PY - 2018 DA - 2018// TI - Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-017-0310-x DO - 10.1186/s40425-017-0310-x ID - Kaufman2018 ER - TY - JOUR AU - D’Angelo, S. P. AU - Russell, J. S. AU - Bhatia, S. AU - Hamid, O. AU - Mehnert, J. M. AU - Terheyden, P. PY - 2018 DA - 2018// TI - 18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.5_suppl.192 DO - 10.1200/JCO.2018.36.5_suppl.192 ID - D’Angelo2018 ER - TY - JOUR AU - Nghiem, P. AU - Bhatia, S. AU - Brohl, A. S. AU - Hamid, O. AU - Mehnert, J. M. AU - Terheyden, P. PY - 2018 DA - 2018// TI - Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.9507 DO - 10.1200/JCO.2018.36.15_suppl.9507 ID - Nghiem2018 ER - TY - STD TI - D’Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020;In Press. ID - ref26 ER - TY - STD TI - R Development Core Team. R: A language and environment for statistical computing [Internet]. R Foundation for Statistical Computing, Vienna, Austria.; 2008. Available from: http://www.R-project.org. UR - http://www.r-project.org ID - ref27 ER - TY - STD TI - Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. PharmacoEconomics . 2019 May 18 [cited 2019 May 31]; Available from: http://link.springer.com/https://doi.org/10.1007/s40273-019-00806-4. ID - ref28 ER - TY - JOUR AU - Royston, P. AU - Parmar, M. K. B. PY - 2002 DA - 2002// TI - Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects JO - Stat Med VL - 21 UR - https://doi.org/10.1002/sim.1203 DO - 10.1002/sim.1203 ID - Royston2002 ER - TY - STD TI - Jackson C, Metcalfe P, Amdahl J. flexsurv: Flexible Parametric Survival and Multi-State Models [Internet]. 2017 [cited 2019 Jan 30]. Available from: https://CRAN.R-project.org/package=flexsurv. UR - https://cran.r-project.org/package=flexsurv ID - ref30 ER - TY - STD TI - Lambert PC. Sensitivity analysis to location of knots (proportional hazards) [Internet]. Paul C. Lambert. 2017 [cited 2019 Aug 29]. Available from: https://www.pclambert.net/software/stpm2/knot_positions_sensitivity/. UR - https://www.pclambert.net/software/stpm2/knot_positions_sensitivity/ ID - ref31 ER - TY - STD TI - Lambert PC. Workshop on Applications and Developments of Flexible Parametric Survival Models [Internet]. In: Satellite meeting to the the Nordic and Baltic Stata Users Group meeting. Stockholm, Sweden; 2011. 10 [cited 2019 Aug 29]; Available from: https://www2.le.ac.uk/Members/pl4/workshop2011-1/Stockholm-Workshop-2011-Paul-Lambert.pdf.. UR - https://www2.le.ac.uk/Members/pl4/workshop2011-1/Stockholm-Workshop-2011-Paul-Lambert.pdf ID - ref32 ER - TY - JOUR AU - Hannan, E. J. AU - Quinn, B. G. PY - 1978 DA - 1978// TI - The determination of the order of an autoregression JO - J R Stat Soc Ser B Stat Methodol VL - 41 ID - Hannan1978 ER - TY - BOOK AU - Burnham, K. P. AU - Anderson, D. R. PY - 2002 DA - 2002// TI - Model selection and multimodel inference : a practical information-theoretic approach PB - Springer-Verlag New York, Inc. CY - United States of America ID - Burnham2002 ER - TY - STD TI - Bullement A, Meng Y, Cooper M, Lee D, Harding TL, O’Regan C, et al. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for health and care excellence: how did the initial best estimate compare to trial data subsequently made available? J Med Econ. 2018;13:1–10. ID - ref35 ER - TY - JOUR AU - Royston, P. AU - Parmar, M. K. PY - 2013 DA - 2013// TI - Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome JO - BMC Med Res Methodol VL - 13 UR - https://doi.org/10.1186/1471-2288-13-152 DO - 10.1186/1471-2288-13-152 ID - Royston2013 ER - TY - JOUR AU - Gibson, E. AU - Koblbauer, I. AU - Begum, N. AU - Dranitsaris, G. AU - Liew, D. AU - McEwan, P. PY - 2017 DA - 2017// TI - Modelling the survival outcomes of Immuno-oncology drugs in economic evaluations: a systematic approach to data analysis and extrapolation JO - PharmacoEconomics. VL - 35 UR - https://doi.org/10.1007/s40273-017-0558-5 DO - 10.1007/s40273-017-0558-5 ID - Gibson2017 ER - TY - STD TI - Bullement A, Latimer NR, Bell Gorrod H. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study. Value Health [Internet]. 2019;22(3):276–83. [cited 2019 Jan 29]). Available from: https://www.valueinhealthjournal.com/article/S1098-3015(18)36202-8/abstract. UR - https://www.valueinhealthjournal.com/article/S1098-3015(18)36202-8/abstract ID - ref38 ER - TY - STD TI - Lanitis T, Proskorovsky I, Ambavane A, Hunger M, Zheng Y, Bharmal M, et al. Survival analysis in patients with metastatic merkel cell carcinoma treated with Avelumab. Adv Ther. 2019;36(9):2327–41. ID - ref39 ER - TY - JOUR AU - Balch, C. M. AU - Buzaid, A. C. AU - Soong, S. J. AU - Atkins, M. B. AU - Cascinelli, N. AU - Coit, D. G. PY - 2001 DA - 2001// TI - Final version of the American joint committee on Cancer staging system for cutaneous melanoma JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.16.3635 DO - 10.1200/JCO.2001.19.16.3635 ID - Balch2001 ER - TY - JOUR AU - Balch, C. M. AU - Gershenwald, J. E. AU - Soong, S. AU - Thompson, J. F. AU - Atkins, M. B. AU - Byrd, D. R. PY - 2009 DA - 2009// TI - Final version of 2009 AJCC melanoma staging and classification JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.23.4799 DO - 10.1200/JCO.2009.23.4799 ID - Balch2009 ER - TY - BOOK AU - Hilbe, J. M. PY - 2011 DA - 2011// TI - Negative binomial regression [internet] PB - Cambridge University Press CY - Cambridge UR - https://doi.org/10.1017/CBO9780511973420 DO - 10.1017/CBO9780511973420 ID - Hilbe2011 ER - TY - JOUR AU - Bullement, A. AU - Nathan, P. AU - Willis, A. AU - Amin, A. AU - Lilley, C. AU - Stapelkamp, C. PY - 2019 DA - 2019// TI - Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma JO - PharmacoEconomics - Open VL - 3 UR - https://doi.org/10.1007/s41669-018-0115-y DO - 10.1007/s41669-018-0115-y ID - Bullement2019 ER - TY - JOUR AU - Dickman, P. W. AU - Coviello, E. PY - 2015 DA - 2015// TI - Estimating and modeling relative survival JO - Stata J VL - 15 UR - https://doi.org/10.1177/1536867X1501500112 DO - 10.1177/1536867X1501500112 ID - Dickman2015 ER - TY - STD TI - Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for cured patients in cost-effectiveness analysis. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2017;20(4):705–9. ID - ref45 ER -